| Featured Products | Mechanism/Target | Indications | PCC IND PH1 PH2 Ph3 | Partner |
|---|---|---|---|---|
|
JMKX3142 JMKX003142JMKX003142 is a selective arginine vasopressin (AVP) V2 receptor (V2R) antagonist that shows promise in improving edema symptoms in patients with nephrotic edema and heart failure with fluid retention, as well as renal function in patients with autosomal dominant polycystic kidney disease (ADPKD). This compound exhibits higher pharmacological activity and is well-tolerated, offering the potential to achieve comparable efficacy while reducing the incidence of adverse events. |
V2R | ADPKD |
|
|
| Renal edema |
|
|||
| JMKX3142-IV | Cardiac edema |
|
||
|
JMKX3002 JMKX003002JMKX003002 is a phosphate absorption inhibitor indicated for the treatment of hyperphosphatemia, one of the most common complications of chronic kidney disease (CKD). Compared to phosphate binders, it is expected to offer improved safety, a lower pill burden, and better phosphate-lowering efficacy when used in combination therapy. |
NHE3 | Hyperphosphatemia (in hemodialysis patients) |
|
|
| JMB-2201 |
|
|||
|
JMKX001899 JMKX001899JMKX001899 is a small-molecule targeted therapy that targets the KRAS G12C mutation and is used to treat solid tumors with the KRAS G12C mutation. Compared to conventional treatments, it is expected to enable precise targeting of tumor cells, enhance antitumor efficacy, reduce side effects, and, as an oral medication, improve treatment adherence. |
KRAS | 2L NSCLC |
Key Clinical Trial |
|
|
JMKX0197 JMKX000197JMKX000197 is an immunostimulant used to treat malignant pleural effusion. By activating inflammatory factors such as interleukins and interferons, it induces chronic inflammation of the pleura, leading to chemical pleuritis. This causes the visceral and parietal pleura to adhere and fuse, thereby slowing or halting the accumulation of pleural fluid. Administered locally, it offers improved safety and is expected to yield better therapeutic outcomes compared to traditional thoracentesis and drainage. |
STING | Malignant pleural effusion |
|
|
| JMB-2301 |
|
|||
| JMKX0189 | S1P1 | CIPN |
|
|
| SLE |
|
|||
| UC |
|
|||
|
JMKX1904 JYB1904JYB1904 Injection is a humanized monoclonal antibody against immunoglobulin E (IgE) obtained through antibody engineering. IgE is involved in the development of various Type 2 inflammatory diseases, including allergic asthma, chronic idiopathic urticaria, and allergic rhinitis. The modified molecular structure enhances affinity for IgE, resulting in a significantly prolonged half-life and more sustained therapeutic effect, thereby supporting longer dosing intervals. |
IgE | Asthma |
|
|
| Chronic white-headed urticaria |
|
|||
| Chronic rhinitis |
|
|||
| JMKX003948 | Hit2a | WAMD |
|
|
| JMKX2992 | AR | Tumor |
|
|
Pipe Layout
The Jeyou Pharmaceuticals Clinical Development Center integrates multiple functions, including clinical medicine, clinical pharmacology, translational medicine, pharmacy, medical statistics, clinical operations, and quality assurance. Its core team consists of seasoned industry experts, many of whom have worked at renowned multinational pharmaceutical companies. The center has achieved a leading domestic position in clinical medical science, statistics, translational medicine, clinical pharmacology, and clinical research project management, ensuring efficient, compliant, well-organized, accurate, and high-quality clinical research.
Guided by clinical needs, the Jeyou Pharmaceuticals Clinical Development Center continuously enhances its clinical translation capabilities and actively advances clinical digitalization. By bridging the gap between clinical trials and information technology, the center collaborates with research institutions and technology providers to improve the standardization and interoperability of clinical data throughout the entire process. This approach enhances the timeliness and accuracy of decision-making, accelerates the pace of all stages from patient recruitment to drug approval, reduces R&D costs, and increases the success rate of R&D.
Jeyou Pharma’s Clinical Development Center continues to promote the translation of clinical research outcomes and actively expands its clinical research footprint. As of the end of 2024, the company has established 336 clinical centers across 29 provinces and municipalities nationwide.
Distribution of Clinical Centers Nationwide
